Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India
- Conditions
- HIV Infections
- Interventions
- Behavioral: Standard ART initiation [usual care]Behavioral: Same-day ART initiation [experimental]Other: Community-based HIV care [experimental]Other: Government-based HIV care [usual care]Behavioral: Routine adherence support [usual care]Behavioral: Enhanced adherence support [experimental]
- Registration Number
- NCT05165810
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
The goal of this study is to improve HIV care outcomes for people who inject drugs (PWID) in India. The study will implement a two-phase trial to evaluate whether HIV treatment outcomes (HIV viral suppression) in HIV infected PWID can be improved with three different interventions: i) by offering a faster treatment start time (same-day antiretroviral therapy \[ART\] initiation vs. standard), ii) by provided community-based HIV care in PWID-focused centers (vs. centralized government-based HIV care) and, iii) providing an enhanced adherence support to participants who experience treatment failure at six months (vs. routine adherence support). The investigators hypothesize that faster access to ART and HIV treatment in PWID-focused community sites will lead to higher levels of initiation and retention to ART compared with standard care; and use of enhanced navigation and psychosocial support to patients who experience treatment failure at six months will lead to improved viral suppression compared with routine adherence support.
- Detailed Description
People who inject drugs (PWID) are at high risk for HIV infection and experience worse antiretroviral therapy (ART) outcomes than other key populations, particularly in low and middle income countries (LMIC). India has the largest number of opioid users in the world, and new injection drug epidemics have emerged in the North and Central regions of the country.
In phase 1, the investigators will evaluate two structural interventions to improve treatment outcomes among HIV-positive PWID in India. First, same-day ART (initiating ART on the day of HIV diagnosis/confirmation rather than waiting until standard evaluations are completed in an HIV clinic), was found to increase viral suppression rates in African studies with generalized HIV epidemics, but has not been evaluated in PWID. The second intervention is community-based HIV care. At present, all publicly-financed HIV treatment is provided at designated government ART centers. In prior work, the investigators found that PWID-centric integrated care centers (ICCs) were effective at engaging the population and increasing HIV testing uptake and were rated favorably by clients in anonymous surveys. ICCs linked HIV-positive PWID to government clinics, but were not equipped to provide primary HIV care. However, ICCs can be scaled-up to provide HIV treatment on-site and the investigators hypothesize this will improve initiation and retention to ART among PWID. The investigators will use a randomized factorial design to determine the individual and joint effects of same-day ART initiation and community-based HIV care. The primary outcome of the phase-1 trial is viral suppression at 6 months, with longer term follow-up to 18 months.
In phase 2, the investigators will evaluate a psychosocial/navigation intervention (enhanced adherence support) among participants who experience treatment failure during the first trial phase, defined as non-suppressed HIV RNA at the 6-month visit. These participants will be randomly assigned (in a second randomization) to enhanced adherence support or routine adherence support. The primary outcome of phase-2 will be viral suppression 6 months following the second randomization (12 months from enrollment in phase-1).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 800
- 18 years of age or older
- Reports injection drug use in prior 24 months
- Documented HIV positive
- Antiretroviral therapy naïve
- HIV RNA 1,000 c/mL or higher
- If previously linked to HIV care, able and willing to provide govt. ART book for documentation of care received.
PHASE 1
- Pregnant (if female)
- Does not speak English, Hindi, or local language
- Plans to migrate in next 12 months
- Not competent to participate in the study or provide written informed consent.
PHASE 2 Inclusion Criteria:
• Participants who experience treatment failure at 6 months (HIV RNA>1000c/mL)
PHASE 2 Exclusion Criteria:
• Participants who do not experience treatment failure at 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Arm 3: standard ART initiation + community-based HIV care + routine adherence support Standard ART initiation [usual care] Participants randomized to Arm 3 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 2: same-day ART + government-based HIV care + routine adherence support Same-day ART initiation [experimental] Participants randomized to Arm 2 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support Standard ART initiation [usual care] Participants randomized to Arm 4 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support Community-based HIV care [experimental] Participants randomized to Arm 8 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 1: standard ART initiation + government-based HIV care + routine adherence support Standard ART initiation [usual care] Participants randomized to Arm 1 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 1: standard ART initiation + government-based HIV care + routine adherence support Routine adherence support [usual care] Participants randomized to Arm 1 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 2: same-day ART + government-based HIV care + routine adherence support Government-based HIV care [usual care] Participants randomized to Arm 2 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 3: standard ART initiation + community-based HIV care + routine adherence support Routine adherence support [usual care] Participants randomized to Arm 3 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support Government-based HIV care [usual care] Participants randomized to Arm 4 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support Enhanced adherence support [experimental] Participants randomized to Arm 4 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support Same-day ART initiation [experimental] Participants randomized to Arm 5 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 1: standard ART initiation + government-based HIV care + routine adherence support Government-based HIV care [usual care] Participants randomized to Arm 1 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 2: same-day ART + government-based HIV care + routine adherence support Routine adherence support [usual care] Participants randomized to Arm 2 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support Community-based HIV care [experimental] Participants randomized to Arm 5 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support Routine adherence support [usual care] Participants randomized to Arm 5 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support Enhanced adherence support [experimental] Participants randomized to Arm 6 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support Standard ART initiation [usual care] Participants randomized to Arm 7 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 3: standard ART initiation + community-based HIV care + routine adherence support Community-based HIV care [experimental] Participants randomized to Arm 3 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\]. Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support Same-day ART initiation [experimental] Participants randomized to Arm 6 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support Government-based HIV care [usual care] Participants randomized to Arm 6 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support Enhanced adherence support [experimental] Participants randomized to Arm 7 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support Same-day ART initiation [experimental] Participants randomized to Arm 8 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support Community-based HIV care [experimental] Participants randomized to Arm 7 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\]. Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support Enhanced adherence support [experimental] Participants randomized to Arm 8 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\].
- Primary Outcome Measures
Name Time Method Number of participants with viral load suppression at 6 months after phase 1 randomization Measured at 6 months after phase 1 randomization HIV RNA ≤1000 c/mL
Number of participants with viral load suppression at 12 months after phase 1 randomization Measured at 6 months after the second randomization (12 months since phase 1 randomization) HIV RNA ≤1000 c/mL. Restricted to participants with treatment failure at 6 months who are allocated to either enhanced or routine adherence support in phase-2 randomization
- Secondary Outcome Measures
Name Time Method Number of participants who adhere to their ART medication refills Measured up to 18 months after phase 1 randomization To determine whether same-day ART, community HIV adherence support, or enhanced care increases indices of the care continuum among HIV-positive PWID, relative to their control conditions.
Number of participants who engage with or are retained on medication for opioid use disorder (MOUD) Measured at 3, 6, 12 and 18 months since phase 1 randomization To determine whether same-day ART, community HIV care, or enhanced adherence support increases use of and retention to medication for opioid use disorder (MOUD) among HIV-positive PWID, relative to their control conditions.
Number of participants with HIV viral suppression in each intervention at non-primary time points Measured at 3, 12 and 18 months since phase 1 randomization HIV RNA ≤1000 c/mL
Mortality rate among participants Measured at 3, 6, 12 and 18 months since phase 1 randomization To determine whether same-day ART, community HIV care, or enhanced adherence support affects mortality among HIV-positive PWID, relative to their control conditions.
Number of participants who report increased quality of life since baseline Measured at 3, 6, 12 and 18 months since phase 1 randomization Self-reported quality of life score based on amended version of validated instrument EQ-5D. To determine whether same-day ART, community HIV care, or enhanced adherence support increases quality of life (QOL) among HIV-positive PWID, relative to their control conditions.
Number of participants who are linked or re-linked (if in care previously) to HIV care Measured up to 18 months after phase 1 randomization To determine whether same-day ART, community HIV care, or enhanced adherence support increases indices of the care continuum among HIV-positive PWID, relative to their control conditions.
Number of participants who initiate or re-initiate ART Measured up to 18 months after phase 1 randomization To determine whether same-day ART, community HIV care, or enhanced adherence support increases indices of the care continuum among HIV-positive PWID, relative to their control conditions.
Number of participants who remain in HIV care Measured up to 18 months after phase 1 randomization To determine whether same-day ART, community HIV care, or enhanced adherence support increases indices of the care continuum among HIV-positive PWID, relative to their control conditions.
Number of participants who experience HIV-related stigma (anticipated, enacted, internalized) Measured at 1, 3, 6, 12 and 18 months since phase 1 randomization Self-reported stigma scores based on 18-item likert scale
Trial Locations
- Locations (1)
POINTER study -YRGCARE
🇮🇳New Delhi, India